CCO Treatment Updates
An Update on Ribavirin Analogues: Meeting the Challenge of Anemia in Hepatitis C Treatment
Treating HCV-infected Patients at High Risk of Anemia
|
Module 1 of 2
|
Program Director:
Patrick Marcellin, MD
|
|
 Topics covered include:
- Introduction
- Incidence of Anemia Related to HCV Therapy
- Impact of Anemia Related to HCV Therapy
- Mechanism of HCV Therapy-related Anemia
- Management of Anemia Related to HCV Therapy
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the factors that reduce the sustained virologic response to optimal treatment, especially ribavirin-associated anemia. Describe optimal treatment for chronic hepatitis C. Review strategies for treating or preventing ribavirin-associated anemia.
|
Ribavirin Analogues and Ribavirin-like Molecules: New Directions in Antiviral Therapy
|
Module 2 of 2
|
Program Director:
Patrick Marcellin, MD
|
|
Topics covered include:
- Introduction
- Ribavirin
- Ribavirin-Associated Anemia
- Viramidine: Preclinical and Early Clinical Studies
- Viramidine
Learning Objectives
Upon completion of this activity, participants should be able to:
Review recent studies of other ribavirin analogues, including levovirin and merimepodib, for the treatment of chronic hepatitis C. Describe the proposed mechanisms underlying the ribavirin-associated anemia. Discuss the recent clinical trials of viramidine for the treatment of chronic hepatitis C.
|
Interactive Case Challenges
Management of Chronic Hepatitis C in a Man with HIV Coinfection
Program Director:
Patrick Marcellin, MD
|
|
 By Raymond T. Chung, MD Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the importance of maintaining ribavirin dose for achieving sustained virologic response Review interventions to reduce ribavirin-associated anemia Describe the proposed mechanisms underlying ribavirin-associated anemia
|
Management of a Treatment-Naive Man with HCV Genotype 1 and Advanced Fibrosis
Program Director:
Patrick Marcellin, MD
|
|
By Raymond T. Chung, MD Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the importance of maintaining ribavirin dose for achieving sustained virologic response Review interventions to reduce ribavirin-associated anemia Describe the proposed mechanisms underlying ribavirin-associated anemia
|
Corresponding PowerPoints for each Module
Speakers' slides from the live symposium
These slide presentations are in Microsoft PowerPoint format. To view the slides in your browser, simply click the 'Download Slides' button. Mac Users: Slides will be downloaded to, and can be accessed from your desktop. You must be logged into the clinicaloptions.com site to view or save the slides.
Treating HCV-infected Patients at High Risk of Anemia
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 527 KB
|
Ribavirin Analogues and Ribavirin-like Molecules: New Directions in Antiviral Therapy
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 373 KB
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by University of Alabama School of Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|